Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 240

Results For "C"

9540 News Found

Gland Pharma receives approval for phytonadione injection emulsion
Drug Approval | December 12, 2024

Gland Pharma receives approval for phytonadione injection emulsion

This product is indicated in coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity.


Biocon Biologics recognized as Asia IP Elite for 2024 by IAM
News | December 12, 2024

Biocon Biologics recognized as Asia IP Elite for 2024 by IAM

Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list


Briefs: Alembic Pharmaceuticals and Veerhealth Care
Drug Approval | December 12, 2024

Briefs: Alembic Pharmaceuticals and Veerhealth Care

The successful completion of RRA assessment by the USFDA, would enable company to open up its business in the USA market


Arvinas and Pfizer presents phase 1b data from the TACTIVE-U sub-study of Vepdegestrant in combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
Clinical Trials | December 11, 2024

Arvinas and Pfizer presents phase 1b data from the TACTIVE-U sub-study of Vepdegestrant in combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium

Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate


LVMH Recherche and Integrated Biosciences partner to discover anti-aging chemical entities
News | December 10, 2024

LVMH Recherche and Integrated Biosciences partner to discover anti-aging chemical entities

Partnership to supercharge LVMH Recherche with Integrated Biosciences’ innovative AI and synthetic biology platform for targeting skin aging


Ichnos Glenmark Innovation presents first clinical data from Phase 1 study of Trispecific TREAT antibody
Clinical Trials | December 10, 2024

Ichnos Glenmark Innovation presents first clinical data from Phase 1 study of Trispecific TREAT antibody

Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma


AbbVie announces emotional impact report on mental health of underrepresented CLL cancer patients
News | December 09, 2024

AbbVie announces emotional impact report on mental health of underrepresented CLL cancer patients

CLL is one of the most common leukemias among adults affecting more than 200,000 people in the US


Merck’s investigational ADC with R-CHP demonstrates 100% response rate for B-cell lymphoma
Clinical Trials | December 09, 2024

Merck’s investigational ADC with R-CHP demonstrates 100% response rate for B-cell lymphoma

Based on data, 1.75 mg/kg dose established as recommended dose for Phase 3 trial of this investigational antibody-drug conjugate